Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Ireland Cancer Center of University Hospitals Case Medical Center and Tracon Pharmaceuticals have treated the first cancer patient in a Phase I clinical trial with TRC102, a novel anticancer drug.
Subscribe to our email newsletter
TRC102 is intended to reverse resistance to Temodar chemotherapy by targeting a specific DNA repair pathway. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary anti-tumor activity, of TRC102 in patients with advanced cancer who are also receiving Temodar. TRC102 is also being developed to reverse resistance to the chemotherapeutic Alimta(r), and a second Phase I trial of TRC102 combined with Alimta(r) is expected to begin later in 2008.
Charles Theuer, president and CEO of Tracon, said: “We view TRC102 as a significant first-in-class therapy that targets an important mechanism of chemotherapy resistance.”